Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens
Key facts
- Where
- Centennial, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07932002, who can take part
Where in United States
- IMMUNOe Research CentersCentennial, United StatesContact: Maureen CollinsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- IMMUNOe Research Centers
- Trial code
- NCT07932002
- Record updated
- 12 November 2026
- Original description
Assessment of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Alleviating Neurological Symptoms Linked to Infectious PathogensRead full original descriptionShow less
Assessment of RUCONEST® (C1 Esterase Inhibitor [Recombinant]) in Alleviating Neurological Symptoms Linked to Infectious Pathogens
Assessment of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Alleviating Neurological Symptoms Linked to Infectious Pathogens
Inclusion: Age 18 and older, male or female; Patient is able to understand and fully participate in the activities of the study and the consent in accordance with federal regulations; Patients who were involved in the previous study with defined post-COVID neurologic symptoms; New patients who have been diagnosed with post-COVID neurologic symptoms.
Exclusion: Receiving any form of C1-INH therapy, either acute or prophylactic treatment; Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study or have discontinued within 30 days of study entry from any other clinical study involving and investigational product; History or suspicion of allergy to rabbits; Neurological conditions related to injury; Neuropathy related to diabetes; History of thrombotic stroke; Abnormal kidney or liver enzymes; Participants who are pregnant or lactating; Largely incapacitated or bed-ridden.